Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ZYRTEC ALLERGY versus MECLIZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ZYRTEC ALLERGY versus MECLIZINE HYDROCHLORIDE.
CHILDREN'S ZYRTEC ALLERGY vs MECLIZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine is a selective antagonist of peripheral H1 histamine receptors, inhibiting histamine-mediated allergic and inflammatory responses.
Meclizine is a histamine H1 receptor antagonist that acts centrally in the vestibular system to suppress nausea and vomiting. It also has anticholinergic and sedative effects.
5 mg (1 tablet or 5 mL oral solution) once daily; dosing frequency may be increased to 10 mg once daily (2 tablets or 10 mL) for more severe symptoms.
25-50 mg orally, 3 to 4 times daily for vertigo; 25-50 mg orally 1 hour before travel, may repeat every 24 hours as needed for motion sickness.
None Documented
None Documented
Terminal half-life 8.5–10.5 hours in children 2–5 years; 9–11 hours in children 6–12 years; 8–9 hours in adults. Clinically, supports once-daily dosing.
Terminal elimination half-life: 6 hours (range 5-10 hours). Clinical context: Supports twice-daily dosing; steady-state achieved in approximately 24 hours.
Primarily renal (60% unchanged) via tubular secretion; 40% metabolized in liver to inactive metabolites excreted in urine; <1% fecal.
Renal (unchanged and metabolites): 50%; fecal: 40%; biliary: 10%
Category C
Category A/B
Antihistamine
Antihistamine